Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 10/20 | 0.68 |
| ▸ | F11 | P03951 | 4/20 | 0.68 |
| ▸ | F7 | P08709 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.38 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 3/20 | 0.38 |
| ▸ | KLK1 | P06870 | 3/20 | 0.38 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918455 | 0.89 | F9 (0.58) | F9F11F7CYP2C9F10 | |
| SCHEMBL1233112 | 0.81 | F9 (1.00) | F9F11F7CYP2C9F10 | |
| SCHEMBL1231106 | 0.81 | F9 (0.76) | F9F11F7CYP2C9F10 | |
| SCHEMBL15291870 | 0.77 | F9 (0.87) | F9F11F7CYP2C9F10 | |
| SCHEMBL6918977 | 0.76 | F9 (0.77) | F9F11F7CYP2C9F10 | |
| SCHEMBL6919853 | 0.76 | F9 (0.71) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607613 | 0.74 | F9 (0.81) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607617 | 0.73 | F9 (0.68) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607615 | 0.73 | F9 (0.68) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607623 | 0.72 | F9 (0.57) | F9F11F7CYP2C9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F9 1/4885F11 5/4885F7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.